Table 3.

Northern New England Cardiovascular Disease Study Group External Validation Patient and Disease Characteristics

	No AKI	AKI	P Value
Procedures (n=27 905)	26 375	1530
Comorbidities
Age	63.79±11.93	69.58±12.40	<0.001
Female	28.69	38.17	<0.001
Nonwhite race	0.15	0.20	0.667
Tobacco use (any)	27.81	20.39	<0.001
Prior comorbidities
Prior PCI	34.13	31.70	0.051
Prior CABG	16.05	19.74	<0.001
Prior MI	26.96	30.07	0.008
Prior stroke	11.22	20.13	<0.001
Diabetes	30.51	47.12	<0.001
Hypertension	74.23	81.76	<0.001
Peripheral vascular disease	17.52	29.48	<0.001
Number of prior comorbid events
CHF	10.45	30.52	<0.001
Shock within prior 24 hours	0.66	4.51	<0.001
Prior renal complications and function
Prior CKD	18.67	43.53	<0.001
eGFR <60, mL/min per m2	17.77	36.01	<0.001
eGFR <45, mL/min per m2	0.77	6.01	<0.001
eGFR <30, mL/min per m2	0.13	1.50	<0.001
Medications
Thrombolytic use	5.04	5.75	0.214
At presentation
Prepresent MI	18.89	25.82	<0.001
Anemia	14.35	23.33	<0.001
Shock	0.79	5.42	<0.001
Unstable angina	0.79	5.42	<0.001
Ejection fraction ≤40%	6.93	15.03	<0.001
Procedural characteristics
Priority
Elective	26.96	11.24	<0.001
Urgent	51.80	53.14	0.31
Emergent	21.20	34.97	<0.001
Salvage	0.03	0.65	<0.001
Ad hoc PCI	83.05	82.36	0.716
Multivessel disease
Number of diseased vessels
Single	58.15	45.56	<0.001
Double	27.21	31.83
Triple	14.64	22.61
Number of stents	1.56±1.04	1.60±1.18	0.1827
Intra‐aortic balloon pump	1.69	11.08	<0.001

AKI indicates acute kidney injury; CABG, coronary artery bypass grafting; CHF, congestive heart failure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PCI, percutaneous coronary intervention.